Theravance Biopharma Inc Announces Results from Phase 2B Study of Izencitinib - Conference Call Transcript
Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma conference call. (Operator Instructions) Also, today's conference is being recorded. And now I'd like to turn the call over to Gail Cohen, Vice President, Corporate Communications. Please go ahead.
Good afternoon, and thank you for joining. As always, I remind you that this call will contain forward-looking statements that involve risks and uncertainties, including statements about our development pipeline, expected benefits of our products, anticipated timing of clinical trials, regulatory filings and expected financial results.
Information concerning factors that could cause results to differ materially from our forward-looking statements is described further in our filings with the SEC. Joining us are Rick Winningham, Chief Executive Officer; and Rick Graham, Senior Vice President, Development.
Following our prepared remarks, we will open the call for questions
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
